Vincent Chung MD

Gastrointestinal Cancer

Clinical Professor

1500 Duarte RdDuarte, CA 91010
Phone+1 626-256-4673
Fax+1 626-301-8233

Dr. Chung is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chung's full profile Already have an account?

Education & Training

Los Angeles County-Harbor-UCLA Medical Center 1Fellowship, Hematology and Medical Oncology, 2002 - 2005
Sutter Health/California Pacific Medical CenterResidency, Internal Medicine, 1998 - 2002
University of Tennessee Health Science Center College of MedicineClass of 1998

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 1999 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2013-2017
CMS Meaningful Use Stage 1 Certification Sunrise Patient Portal and Sunrise Ambulatory Care EHR, Allscripts, 2013-2017
CMS Meaningful Use Stage 2 Certification Sunrise Ambulatory Care, Allscripts, 2013-2017

Clinical Trials

Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2003 Dec 22
COMPLETED
PHASE2
Dasatinib in Treating Patients With Stage IV Pancreatic Cancer
TERMINATED
PHASE2
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
COMPLETED
PHASE1

Publications & Presentations

PubMed

A phase 1 study of orally administered 5-fluoro-2'-deoxycytidine with tetrahydrouridine in patients with refractory solid tumors.
Alice P Chen, Shivaani Kummar, Larry Rubinstein, Jennifer Zlott, Geraldine O'Sullivan Coyne
Cancer Chemotherapy and Pharmacology. 2025-12-22
8 citations
Therapeutic Targeting of Oncogene-Induced Transcription-Replication Conflicts in Pancreatic Ductal Adenocarcinoma.
Shanna J Smith, Fan Meng, Robert G Lingeman, Caroline M Li, Min Li
Gastroenterology. 2025-09-01
14 citations
Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma.
Jordan M Cloyd, Angela Sarna, Matthew J Arango, Susan E Bates, Manoop S Bhutani
JAMA Surgery. 2025-02-01

Lectures

Gene expression profiling of unresectable pancreatic cancer patients treated with gemcitabine, nab-paclitaxel, metformin, and dietary supplements (DS).
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
First-time in-human study of VMD-928, an allosteric and irreversible TrkA selective inhibitor, in patients with solid tumors or lymphoma.
2019 ASCO Annual Meeting - 6/1/2019
A SU2C catalyst randomized phase II trial of pembrolizumab with or without paricalcitol in patients with stage IV pancreatic cancer who have been placed in best possib...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

US Cancer Clinics Scramble to Get Experimental Revolution Medicines Pancreatic Cancer DrugMay 14th, 2026
Late-Breaking Analysis Demonstrates Characteristics Associated with Long-Term Overall Survival with Onivyde® Regimen in Metastatic Pancreatic AdenocarcinomaMay 31st, 2025
City of Hope to Present Latest Research on Breast Cancer, Supportive Care, Kidney Cancer, and More at 2025 ASCO Annual MeetingMay 7th, 2025